吉兰-巴雷综合征预后不良患者第二剂静脉免疫球蛋白的随机对照试验
SID-GBS试验在荷兰59家医院纳入327例吉兰-巴雷综合征患者,其中112例预后不良。93例改良意向性分析中,49例接受第二剂静脉免疫球蛋白(2 g/kg,5天),44例接受安慰剂。研究不支持对预后不良患者使用第二剂静脉免疫球蛋白。
要点
- 第二剂静脉免疫球蛋白未改善预后不良吉兰-巴雷综合征患者4周残疾评分。
- 第二剂组严重不良事件发生率35%,高于安慰剂组的16%,包括血栓栓塞事件。
- 预后不良的吉兰-巴雷综合征患者不应考虑第二剂静脉免疫球蛋白治疗。
核心结论
- 研究不提供证据表明预后不良的吉兰-巴雷综合征患者从第二剂静脉免疫球蛋白中获益。
- 第二剂静脉免疫球蛋白带来严重不良事件风险,包括血栓栓塞事件。
- 因预后不良而不应考虑第二剂静脉免疫球蛋白治疗吉兰-巴雷综合征。
- 结果提示需要对严重受累的吉兰-巴雷综合征患者进行其他免疫调节剂的治疗试验。
研究设计与样本
- 随机、双盲、安慰剂对照试验(SID-GBS),在荷兰59家参与医院进行。
- 纳入年龄≥12岁、接受标准静脉免疫球蛋白治疗(2 g/kg,5天)第一天的吉兰-巴雷综合征患者。
- 仅改良Erasmus吉兰-巴雷综合征结局评分≥6分的预后不良患者,在纳入后7-9天按中心分层区组随机分配至第二剂静脉免疫球蛋白(2 g/kg,5天)或安慰剂。
- 主要结局为纳入后4周的吉兰-巴雷综合征残疾评分。
- 改良意向性分析纳入93例预后不良患者:49例(53%)接受第二剂静脉免疫球蛋白,44例(47%)接受安慰剂。
主要发现
- 第二剂静脉免疫球蛋白组在最初30天内严重不良事件发生率为35%,安慰剂组为16%。
- 严重不良事件包括血栓栓塞事件。
- 干预组4例患者在随机化后13-24周死亡。
临床怎么用
- 对预后不良的吉兰-巴雷综合征患者,不应考虑给予第二剂静脉免疫球蛋白。
- 需关注第二剂静脉免疫球蛋白相关的严重不良事件,包括血栓栓塞事件。
- 应考虑对严重受累的吉兰-巴雷综合征患者开展其他免疫调节剂的治疗试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barré syndrome with a predicted poor outcome. METHODS: In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (≥12 years) with Guillain-Barré syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of ≥6) according to the modified Erasmus Guillain-Barré syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7-9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barré syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. This study is registered with the Netherlands Trial Register, NTR 2224/NL2107. FINDINGS: Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barré syndrome disability score at 4 weeks was 1·4 (95% CI 0·6-3·3; p=0·45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13-24 weeks after randomisation). INTERPRETATION: Our study does not provide evidence that patients with Guillain-Barré syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other immune modulators in patients severely affected by Guillain-Barré syndrome. FUNDING: Prinses Beatrix Spierfonds and Sanquin Plasma Products.
引用
- Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021. PMID: 33743237. doi:10.1016/S1474-4422(20)30494-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。